The p53 tumor suppressor promotes cell cycle arrest or apoptosis in response to diverse stress stimuli. p53-mediated cell death depends in large part on transcriptional up-regulation of target genes. One of these targets, P53-induced protein with a death domain (PIDD), was shown to function as a mediator of p53-dependent apoptosis. Here we show that PIDD is a cytoplasmic protein, and that PIDD-induced apoptosis and growth suppression in embryonic fibroblasts depend on the adaptor protein receptorinteracting protein (RIP)-associated ICH-1͞CED-3 homologous protein with a death domain (RAIDD). We provide evidence that PIDD-induced cell death is associated with the early activation of caspase-2 and later activation of caspase-3 and -7. Our results also show that caspase-2 ؊/؊ , in contrast to RAIDD ؊/؊ , mouse embryonic fibroblasts, are only partially resistant to PIDD. Our findings suggest that caspase-2 contributes to PIDD-mediated cell death, but that it is not the sole effector of this pathway.
T
he tumor suppressor p53 is a sequence-specific transcription factor that promotes cell cycle arrest or apoptosis in response to cellular stress (1) . Transcriptional activation of the p21 WAF1 cyclin-dependent kinase inhibitor plays a key role in the induction of cell cycle arrest by p53 (2) . p53-dependent apoptosis is regulated, at least in part, by transcriptional activation of its target genes (3) , and this process highly depends on cytochrome c release and the Apaf-1͞caspase-9 activation pathway (4, 5) . Although a number of candidate p53-effector molecules have been reported, it is yet unclear whether each contributes a part of the full response, or whether specific subsets of these genes are required for death in different cell types or in response to different signals (3) .
Among the identified apoptotic effectors of p53, P53-induced protein with a death domain (PIDD)͞leucine-rich DD (LRDD) is a 915-aa protein in mice (910 aa in humans) containing seven tandem LR repeats in the N terminus and a DD in the C terminus (6, 7) . The dual domain structure of PIDD suggests that it may function as a key adapter protein that links additional components of the p53 apoptosis pathway. Using the method of differential display, PIDD was identified as a p53-up-regulated gene in a p53-null Friend-virus-transformed mouse erythroleukemia cell line (DP16.1͞p53ts) that stably expresses a temperature-sensitive (ts) Trp-53 mutant allele. DP16.1͞p53ts cells undergo apoptosis after expression of the wild-type p53 conformation at 32°C. PIDD mRNA is induced by ␥-irradiation in a p53-dependent manner, and the basal level of PIDD mRNA depends on p53 gene status. Overexpression of PIDD also inhibits cell growth in a p53-like manner by inducing apoptosis. Antisense inhibition of PIDD expression was shown to attenuate apoptosis in response to p53 activation and DNA damage, suggesting that PIDD expression is required for p53-dependent death (7) .
Recently, PIDD was found to be present in a large protein complex containing caspase-2 and the adapter protein receptorinteracting protein (RIP)-associated ICH-1͞CED-3 homologous protein with a DD (RAIDD) (8) . The DD of PIDD was shown to interact with the DD of RAIDD, which, in turn associated with caspase-2 through the caspase-recruitment domain (CARD). This study concluded that PIDD was involved in the activation of caspase-2. The role of caspase-2 in apoptosis is uncertain; caspase-2-deficient and wild-type cells (thymocytes and B and T lymphoblasts) are equally sensitive to diverse apoptotic stimuli (9) , yet RNA interference experiments and caspase-2 inhibitors have implicated caspase-2 in stress-induced apoptosis in some cell types (10, 11) . Caspase-2 can act upstream of the mitochondria by inducing Bid cleavage, Bax translocation to the mitochondria, and subsequent cytochrome c release (10) (11) (12) . It can also directly induce the release of cytochrome c from purified mitochondria (11, 12) . Thus, it appears that under certain circumstances, caspase-2 activation may be an early event that engages the mitochondrial apoptotic pathway. The role of RAIDD in apoptosis is also uncertain. RAIDD was initially identified as a death adapter protein capable of binding RIP and caspase-2 through its DD and CARD, respectively (13, 14) . In the presence of RIP and TRADD, RAIDD was found to promote apoptosis by recruiting caspase-2 to TNF receptor 1. Dominant negative forms of RAIDD, however, did not abrogate TNF-mediated cell death (14) .
In this study, we generated mice carrying a null mutation in the RAIDD gene. We report that RAIDD-deficient mice have normal development and lymphocyte populations, and that RAIDD Ϫ/Ϫ thymocytes are sensitive to various cytotoxic agents. RAIDD Ϫ/Ϫ mouse embryonic fibroblasts (MEFs) are sensitive to TNF and cycloheximide; thus, RAIDD is not necessary for TNF-mediated apoptosis in embryonic fibroblasts. To determine the functional significance of the PIDD-RAIDD-caspase-2 complex in promoting cell death, we examined the apoptotic activity of PIDD in RAIDD Ϫ/Ϫ and caspase-2 Ϫ/Ϫ MEFs. We show that PIDD-induced apoptosis and growth suppression depend entirely on RAIDD. We provide evidence that PIDD-induced cell death is associated with the early activation of caspase-2 and later activation of caspase-3 and -7. The early activation of caspase-2 suggests that it may act as a proximal effector of the apoptotic pathway initiated by PIDD and is consistent with recent evidence that caspase-2 functions as an initiator caspase during apoptosis. Our results also show that caspase-2 Ϫ/Ϫ MEFs, Abbreviations: DD, death domain; PIDD, p53-induced protein with a DD; mPIDD, mouse PIDD; RAIDD, receptor-interacting protein-associated ICH-1͞CED-3 homologous protein with a DD; LRDD, leucine-rich DD; ts, temperature sensitive; MEF, mouse embryonic fibroblast; FADD, Fas-associated DD; IRES, internal ribosome entry site. § To whom correspondence may be addressed. E-mail: tmak@uhnres.utoronto.ca or benchimo@uhnres.utoronto.ca. in contrast to RAIDD Ϫ/Ϫ MEFs, are only partially resistant to PIDD, suggesting that, although caspase-2 contributes to PIDDmediated cell death, it is not the sole effector of this pathway. Antibody Production. Rabbits were immunized with a His-tagged mouse PIDD fragment (residues 141-915) purified from BL-21 (DE3) bacteria transformed with the construct pET 28a-mouse PIDD (mPIDD) (Invitrogen). Briefly, after induction with isopropyl-1-thio-␤-D-galactopyranoside, bacteria were collected by centrifugation and lysed, and recombinant protein was purified on a resin of Ni2ϩ affinity by standard affinity purification procedures. The fractions containing purified recombinant PIDD were dialyzed overnight, lyophilized to concentrate the protein, resuspended in PBS, and used to immunize rabbits. The resulting anti-PIDD rabbit serum was purified on a Protein A͞G Sepharose column (Amersham Pharmacia Biosciences). Sera were mixed with borate buffer (25 mM sodium borate͞100 mM boric acid͞75 mM NaCl) and loaded onto the column at a slow flow rate. The column was then washed with borate buffer, and purified antibody was eluted by using 0.1 M glycine buffer. The antibody fractions were neutralized with 1 M Tris buffer and concentrated by using a centrifugal filter device (Millipore).
Experimental Procedures Generation of RAIDD
Plasmids. Mouse wild-type p53 cDNA was excised from pECM53 (18) and cloned into the EcoRI and XbaI sites of pcDNA3.1. Mouse PIDD cDNA was PCR-amplified from pcDNA3.1-mPIDD (7) and cloned into pcDNA3.1-Nterm-Myc͞his to generate a 5Ј Myc-tagged mPIDD construct. 3Ј Myc-tagged mouse PIDD plasmid was generated by PCR amplification from pcDNA3.1-mPIDD using primers that included a Myc-tag before the stop codon. pMIG-IRES-GFP (IRES, internal ribosome entry site) served as the expression vector for mPIDD. PIDD cDNA was excised from pcDNA3.1-mPIDD (7) and cloned into the XhoI and HpaI sites of pMIG.
Retroviral Infection. 293TV cells (3 ϫ 10 5 ) were plated in a 6-cm dish, incubated for 24 h, and then transfected by FuGENE 6 (Roche Applied Science, Indianapolis) with 1 g of a retroviral plasmid and 1 g of pCL-ECO (15 h at 37°C). After transfection, media were removed and replaced with 5 ml of DMEM-H21 supplemented with 10% FCS. After 48 h, the virus-containing medium was collected, filtered (0.45 m, Millipore), and used for infection immediately or frozen at Ϫ80°C. Target fibroblasts were plated at 3 ϫ 10 5 per 10-cm dish and incubated overnight. For infections, the culture medium was replaced with a mixture of fresh media and viral supernatant supplemented with 8 g͞ml polybrene (Sigma) and incubated at 37°C for 12 h. Clonogenic Assays. For long-term colony assays, established MEFs derived from RAIDD Ϫ/Ϫ , FADD Ϫ/Ϫ , caspase-2 Ϫ/Ϫ , and caspase-8 Ϫ/Ϫ mice were plated at 3 ϫ 10 5 cells per 10-cm plate. The next day, MEFs were coinfected with pMIG-IRES-GFP or pMIG-PIDD-IRES-GFP together with pBabe-Hygro using viral supernatants at a volume ratio of 10:1. At 12 h after infection, media was replaced with DMEM with 10% FCS. After a recovery period of 12 h, selection in hygromycin (Invitrogen) was started. Resistant colonies were counted 7 or 8 days after the start of drug selection. For clonogenic assays involving Apaf1 Ϫ/Ϫ MEFs, cells were plated at 9 ϫ 10 5 per 10-cm plate. The next day, cells were transfected overnight (FuGENE 6) with pcDNA3.1 or pcDNA3.1-PIDD together with a plasmid expressing zeomycin resistance. The next day, cells were split and incubated overnight at 37°C, and then selection with zeocin (Invitrogen) was started. Resistant colonies were counted 7 days after the start of selection.
Apoptosis Assay. Two assays were used for detection of apoptotic cells, annexin V staining and assessment of morphology. DP16.1 cells were cultured at 3 ϫ 10 6 per ml and transfected by using FuGENE 6 for 3 h with pcDNA3.1, pcDNA3.1-mp53, or pcDNA3.1-mPIDD together with a plasmid expressing CD20. After 48 h, cells were stained with anti-CD20-FITC (BD Biosciences) according to the manufacturer's protocol, and apoptosis was assessed by annexin V-phycoerythrin staining of CD20-positive cells.
For assessment of apoptosis by morphology, E1A͞ras-transformed RAIDD Ϫ/Ϫ and RAIDD ϩ/ϩ MEFs were plated at 2 ϫ 10 4 cells per chamber. The next day, MEFs were infected for 12 h with pMIG or pMIG-mPIDD. At 48 h after infection, MEFs were fixed and permeabilized as described above and visualized by Hoechst 33258 staining. MEFs were also treated with a combination of 2 g͞ml cycloheximide (Sigma) and 10 ng͞ml recombinant murine TNF-␣ (R & D Systems) before assessment of apoptotic morphology. Cells were examined for apoptotic morphology under a Leica DM LB microscope.
Results
Generation of RAIDD ؊/؊ Mutant Mice. The targeting strategy to generate RAIDD-deficient mice is described in Supporting Text. Southern and Northern blots were performed to confirm the presence of the rearranged allele and lack of RAIDD RNA expression in mouse tissues (see Fig. 6 , which is published as supporting information on the PNAS web site). RAIDDdeficient mice have normal development and lymphocyte populations (data not shown). Absence of RAIDD is also not detrimental to normal lymphocyte proliferation in response to various mitogens, including Con A, anti-CD3, anti-CD3 ϩ anti-CD28, and LPS (data not shown). In addition, we found that RAIDD Ϫ/Ϫ thymocytes were sensitive to various cytotoxic agents, including dexamethasone, ␥-radiation, etoposide, and staurosporine (data not shown).
PIDD Protein Expression.
To investigate PIDD protein expression, we generated a polyclonal antibody against a portion of the mouse PIDD protein (residues 141-915). Antibody specificity was validated by the results of Western blotting and immunoprecipitation presented in Fig. 1 . Ectopically expressed Myctagged PIDD was detected both with a Myc monoclonal antibody and our PIDD polyclonal antibody (Fig. 1 A) . In addition, endogenous PIDD, which migrated as a protein species of Ϸ110 kDa, was detected with the polyclonal antibody. We examined PIDD protein induction in DP16.1͞p53ts cells in response to p53 activation at 32°C by immunoprecipitation͞Western blot analysis. Endogenous PIDD protein levels increased within 8 h of p53 activation and remained elevated for 16 h (Fig. 1B) . This pattern of expression is similar to that of PIDD mRNA in DP16.1͞p53ts cells (7) . Immunofluorescent staining of ectopically expressed Myc-PIDD protein using our PIDD antibody or Myc antibody revealed cytoplasmic localization in Saos-2 cells (Fig. 1C) .
We next examined endogenous PIDD expression in response to DNA damage in p53-expressing human H460 lung cancer cells and in MEFs. Treatment of H460 cells with adriamycin resulted in PIDD protein accumulation by 16 h (Fig. 1D) . ␥-Irradiated MEFs showed PIDD accumulation within 4 h of treatment (Fig.  1E) . Interestingly, a smaller fragment of Ϸ55 kDa was observed in both H460 cells and in MEFs after DNA damage and likely represents a specific cleavage fragment similar to one reported previously (8) .
PIDD-Induced Apoptosis Depends on RAIDD. We showed previously that ectopically expressed PIDD promotes apoptosis in K562 cells (7) . PIDD also promotes apoptosis in p53-null DP16.1 murine erythroleukemia cells ( Fig. 2A) on the basis of Annexin V staining as well as in Saos-2 cells by nuclear morphology (data not shown). PIDD was shown recently to interact with RAIDD and to promote the activation of caspase-2 (8). To determine whether the apoptotic function of PIDD depends on its interaction with RAIDD, we compared PIDD-induced apoptosis in RAIDD ϩ/ϩ and RAIDD Ϫ/Ϫ MEFs. MEFs from RAIDD-deficient and littermate controls were first transformed with the E1A and Ras oncogenes to increase their sensitivity to undergo apoptosis. (E) MEFs were exposed to ␥ radiation (6 Gy) and at the indicated times after irradiation, cell extracts were prepared and subjected to immunoblotting with PIDD antibodies. Transformed MEFs were then retrovirally infected with empty vector (pMIG) or pMIG-PIDD and assessed for apoptosis on the basis of morphological changes, including chromatin condensation and nuclear fragmentation as revealed by staining with Hoechst 33258 (Fig. 2B) . The data are summarized in Fig. 2C and show that RAIDD Ϫ/Ϫ MEFs are completely resistant to PIDD-induced apoptosis. We confirmed that RAIDD protein was expressed in RAIDD ϩ/ϩ MEFs, that it was absent in RAIDD Ϫ/Ϫ MEFs (Fig. 3A) , and that the level of ectopic PIDD expression was similar in both cell types (Fig. 3B) . A similar pattern of PIDD cleavage fragments was also observed in pMIG-PIDD-infected RAIDD ϩ/ϩ and RAIDD Ϫ/Ϫ MEFS (Fig.  3B) . Both RAIDD ϩ/ϩ and RAIDD Ϫ/Ϫ MEFs were equally sensitive to TNF-␣-induced apoptosis (Fig. 2C) .
Activation of Caspase-2, -3, and -7 in PIDD-Expressing MEFs. The resistance of RAIDD Ϫ/Ϫ MEFS to PIDD-induced apoptosis represents the only phenotype we have been able to measure thus far in cells that lack RAIDD and highlights an important role for RAIDD in PIDD-induced apoptosis. We proceeded, therefore, to characterize further the apoptotic response of PIDD-expressing MEFS. Western blots were performed to monitor the processing of procaspase-2, -3, -7, -8, and -9 in RAIDD ϩ/ϩ and RAIDD Ϫ/Ϫ MEFs at different times after infection with pMIG-PIDD or pMIG (Fig.  3B) . Elevated PIDD expression was observed in the pMIG-PIDDinfected cells within 24 h after infection and remained high after 72 h. Strikingly, procaspase-2 processing occurred early after PIDD expression only in RAIDD ϩ/ϩ MEFs and not in RAIDD Ϫ/Ϫ MEFs and preceded the processing of procapsase-3 and -7 (Fig. 3B) . Processing of procaspase-8 and -9 was not detected in PIDDexpressing MEFs of either genotype (Fig. 3B) . Hence, PIDD expression leads to the processing of procaspase-2, -3, and -7, and this processing depends on RAIDD. Complementary experiments performed with fluorogenic peptide substrates demonstrated an increase (2.6-fold) in caspase-3͞-7 activation (DEVD cleavage) in lysates prepared from PIDD-expressing ϩ͞ϩ MEFs and a lack of caspase-8 (IETD cleavage) and caspase-9 (LEHD cleavage) activity (Fig. 3C) . We detected only a slight increase (1.2-fold) in caspase-2 activity (VDVAD cleavage) in the PIDD-expressing ϩ͞ϩ MEFs (Fig. 3C) , even though procaspase-2 was completely processed, as reflected by the disappearance of the full length protein on Western blots. As a control, we treated ϩ͞ϩ MEFs with TNF-␣ and detected activation of caspase-2 (3.3-fold), caspase-3͞-7 (8.9-fold), caspase-8 (1.8-fold), and caspase-9 (2.0-fold).
PIDD-Dependent Growth Suppression Depends on RAIDD and Partially
on Caspase-2 and -8. To investigate further the involvement of RAIDD in PIDD-induced cell death, we compared the ability of PIDD to inhibit the growth of E1A͞Ras-transformed RAIDD ϩ/ϩ and RAIDD Ϫ/Ϫ MEFs. We used a colony-forming assay, because long-term clonogenic assays provide a more stringent measurement of cell survival than short-term assays. MEFs (RAIDD ϩ/ϩ and RAIDD Ϫ/Ϫ ) were coinfected with retroviruses expressing resistance to hygromycin (pBabe-hygro) together with pMIG or pMIG-PIDD. Cells were placed under hygromycin selection 1 day after infection, and we enumerated the drug-resistant colonies Ϸ1 week later. In multiple independent experiments, PIDD-dependent growth suppression was completely abolished in the absence of RAIDD (Fig. 4A) . The requirement of RAIDD for PIDD-dependent apoptosis (Figs. 2 and 3 ) and growth suppression (Fig. 4) indicates that the RAIDD adapter molecule plays an essential role in mediating PIDD-dependent death in MEFs.
Having shown that PIDD expression leads to RAIDDdependent procaspase-2 processing and activation, we proceeded to evaluate the role of caspase-2 in PIDD-mediated growth suppression using caspase-2 ϩ/ϩ and caspase-2 Ϫ/Ϫ MEFs. The ability of PIDD to suppress colony formation was attenuated but not abolished in caspase-2 Ϫ/Ϫ MEFs (Fig. 4B) . This suggests that caspase-2 contributes to PIDD-mediated cell death, but that it is not the sole effector of this pathway. Because RAIDD and caspase-2 appear to act upstream of the mitochondria, we sought to determine whether PIDD acted predominantly through the mitochondrial apoptotic pathway. Apaf-1 is considered a central element in the mitochondrial pathways of apoptosis, in response to a wide range of apoptotic stimuli (17) . Because Apaf-1 Ϫ/Ϫ MEFs were shown to be partially resistant to a variety of apoptotic stimuli, we examined the susceptibility of these cells to PIDD-induced growth inhibition in a colony assay. Apaf-1
Ϫ/Ϫ
MEFs were partially resistant to PIDD-dependent colony suppression (Fig. 4C) .
The observation that caspase-2 Ϫ/Ϫ and Apaf-1 Ϫ/Ϫ MEFs are only partially resistant to PIDD-induced colony suppression, whereas RAIDD Ϫ/Ϫ MEFs are fully resistant, raised the possibility that other initiator caspases may act downstream of PIDD and RAIDD to promote cell death. We therefore tested the MEFs were partially resistant to PIDD-dependent colony suppression (Fig. 4 D and E) . Partial resistance to PIDD-induced growth suppression was also observed in wild-type MEFs and human SkBr3 cells expressing FADD dominant negative (FADD-DN) (data not shown). These data suggest that FADD and caspase-8, two components of the extrinsic pathway of apoptosis, may contribute to the ability of PIDD to suppress the growth of MEFs. The potential involvement of FADD is notable, because PIDD can also interact with FADD (6) (Fig. 5) . We expressed Myc-tagged PIDD in Saos-2 cells and detected binding to endogenous FADD by immunoprecipitation͞Western blotting (Fig. 5A) . We also detected an interaction between endogenous PIDD and endogenous FADD in H460 cells either left untreated or treated with adriamycin (Fig. 5B ). These data demonstrate that PIDD and FADD interact under physiological conditions, and that this interaction is not affected by DNA damage. We estimate that a small proportion of PIDD protein in the H460 cell extract is bound to FADD based on quantitative immunoprecipitation of FADD (data not shown) and the total amount of PIDD protein present in these cells (Fig. 1D) .
To evaluate the possibility that PIDD-induced growth suppression of caspase-2 Ϫ/Ϫ and Apaf-1 Ϫ/Ϫ MEFs is mediated through a pathway that involves FADD and caspase-8, we generated dominant negative FADD (FADD-DN)-expressing caspase-2 Ϫ/Ϫ MEFs and tested these cells in a colony assay. Caspase-2 Ϫ/Ϫ MEFs and caspase-2 Ϫ/Ϫ MEFs expressing FADD-DN were equally sensitive to PIDD-induced cell death (data not shown). Hence, the combined loss of caspase-2 and FADD (by expression of FADD-DN in caspase-2 Ϫ/Ϫ cells) provided no additional survival advantage over that seen with the loss of caspase-2 alone.
Discussion
In this study, we have generated RAIDD Ϫ/Ϫ mice and used embryonic fibroblasts from these mice to investigate the functional significance of the recently reported interaction between RAIDD and PIDD (8) . Several important observations arise from these studies. First, RAIDD Ϫ/Ϫ mice have normal development and normal lymphocyte populations; TNF-induced killing of embryonic fibroblasts is normal in the absence of RAIDD; and thymocytes from RAIDD Ϫ/Ϫ mice respond normally to various apoptosis-inducing agents. Hence, these studies failed to identify a critical role for RAIDD either in mouse development or cellular apoptosis. In a second series of experiments designed to test the functional significance of a protein complex containing RAIDD, caspase-2, and PIDD, we found that the apoptotic activity of PIDD in embryonic fibroblasts depended completely on RAIDD and only partly on caspase-2. The resistance of RAIDD Ϫ/Ϫ MEFs to PIDD-induced apoptosis represents the only phenotype that we have been able to measure thus far in cells that lack RAIDD and highlights an important role for RAIDD in PIDD-induced apoptosis.
PIDD was identified as a p53-up-regulated gene involved in mediating p53-dependent apoptosis (7) . The ability of PIDD to interact with two cytoplasmic adaptor molecules RAIDD and FADD suggests that PIDD may engage the apoptotic machinery at different levels. Despite the overwhelming evidence indicating that p53 promotes apoptosis through the mitochondrial pathway (4, 5) , compelling evidence supports a relationship between p53 and the death receptor pathway of apoptosis (19) . Interestingly, p53-mediated cell death can be attenuated by overexpression of c-Flip-s, a specific inhibitor of caspase-8, and by pharmacological inhibition of caspase-8, at least in some cell types (20, 21) . Our findings indicate that enforced PIDD expression promotes cell death through the activation of both the RAIDD͞caspase-2 and FADD͞caspase-8 pathways. Therefore, PIDD may represent yet another link between the extrinsic and the intrinsic apoptotic pathways.
The absence of phenotype associated with RAIDD and caspase-2 deficiency in mice raises a question regarding the role of PIDD in vivo. The physiological role of PIDD remains unknown; it may be important for apoptosis in some cell types and in response to specific apoptotic signals. Once we have a better understanding of PIDD function in vivo, the importance of RAIDD and caspase-2 as physiological effectors of PIDDdependent apoptosis can be investigated by using the mouse lines and reagents developed in this study.
